[CAS NO. 223568-55-6] EP1013
PRODUCTS SPECIFICATIONS [223568-55-6]
DESCRIPTION [223568-55-6]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 382.38 |
| Molecular Formula | C18H23FN2O6 |
| SMILES | O=C(O)C[C@H](NC([C@H](C(C)C)NC(OCC1=CC=CC=C1)=O)=O)C(CF)=O |
Summary
IC50 & Target
|
Caspase |
In Vivo
EP1013 (1, 3, 10 mg/kg) significantly improves marginal islet mass function. Two animals in the 10 mg/kg EP1013 treatment group exhibit primary islet graft nonfunction, but the diabetes reversal rate for this group is not significantly different from the 3 mg/kg EP1013, 1 mg/kg EP1013, or 10 mg/kg zVAD groups. EP1013 therapy enhances functional syngeneic islet mass and promotes longevity of islet graft function [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 261.52 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.6152 mL | 13.0760 mL | 26.1520 mL |
| 5 mM | 0.5230 mL | 2.6152 mL | 5.2304 mL |
| 10 mM | 0.2615 mL | 1.3076 mL | 2.6152 mL |
